当前位置:首页>产品中心>单抗/多抗>HEK293T Human CD38/ADPRC 1 Stable Cell Line|HEK293T人CD38/ADPRC1稳定细胞系(靶标:人CD38/ADPRC1稳定表达细胞系)

HEK293T Human CD38/ADPRC 1 Stable Cell Line|HEK293T人CD38/ADPRC1稳定细胞系(靶标:人CD38/ADPRC1稳定表达细胞系)

  • 货号:RB9THB691818
  • 价格:面议
  • 点击:364
   一键复制产品信息 复制成功!

产品介绍

产品参数

宿主种属HEK293T
应用FCM
靶标CD38/ADPRC 1
稳定性和储存Frozen in liquid nitrogen.
登录号P28907
背景信息

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38/ADPRC 1) is a ~34 kDa protein. Multifunctional transmembrane glycoprotein able to exert enzymatic activities and also to mobilize calcium, to transduce signals, to adhere to hyaluronan and to other ligands. Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion. Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+). Has cADPR hydrolase activity. CD38 is the therapeutic target of daratumumab (Darzalex).

1. Tohgo, A. et al. (1994) The Journal of biological chemistry 269, 28555-7. PMID: 7961800
2. Takasawa, S. et al. (1993) The Journal of biological chemistry 268, 26052-4. PMID: 8253715
3. Moreschi, I. et al. (2006) Biochemical and biophysical research communications 345, 573-80. PMID: 16690024
4. Deaglio, S. et al. (1998) Journal of immunology (Baltimore, Md. : 1950) 160, 395-402. PMID: 9551996
5. Frasca, L. et al. (2006) Blood 107, 2392-9. PMID: 16293598
6. Deaglio, S. et al. (2001) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 15, 580-2. PMID: 11259373
产品特性Growth Properties: Adherent
种属Human
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 540
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 530
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 451
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 599
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 660
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 662
Anti-Burosumab Neutralizing Recombinant Antibody |抗布罗索尤单抗中和重组抗体(靶标:布罗索尤单抗中和抗体) 374
Anti-Burosumab Neutralizing Recombinant Antibody |抗布罗索尤单抗中和重组抗体(靶标:布罗索尤单抗中和抗体) 414
Anti-Burosumab Non-Neutralizing Recombinant Antibody|抗布罗索尤单抗非中和重组抗体(靶标:布罗索尤单抗非中和抗体) 491
Anti-Rituximab Non-Neutralizing Recombinant Antibody |抗利妥昔单抗非中和重组抗体(靶标:利妥昔单抗非中和抗体) 524
Anti-Rituximab Non-Neutralizing Recombinant Antibody |抗利妥昔单抗非中和重组抗体(靶标:利妥昔单抗非中和抗体) 469
Anti-Rituximab Neutralizing Recombinant Antibody |抗利妥昔单抗中和重组抗体(靶标:利妥昔单抗中和抗体) 651
Anti-Rituximab Neutralizing Recombinant Antibody |抗利妥昔单抗中和重组抗体(靶标:利妥昔单抗中和抗体) 580
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 588
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 590
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 575
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 347
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 447
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 431
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 331
总计 33037 个记录,共 1652 页,当前第 1644 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00